Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.04 (overall 0.03) | 0.04 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 6861
Sealed predictions
- TMED5 in dopamine neurons, braak-0.12 (p 0.767) → +0.39 (p 0.293)receipt 6868
Swarm cases
receipt 6868: TMED5 in dopamine neurons, braak
- power
- full sample +0.17 (p 0.504, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.13 (p 0.597, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.493, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.35, sign flips 0; without severely affected donors +0.17 (p 0.504, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.60 (p 0.0086, n 18) vs +0.17 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMED5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TMED5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.68 p 0.016 (needs p < 3.0e-4)
Receipts
loading the receipts